---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-016489"
form_type: "8-K"
ticker: "RANI"
cik: "0001856725"
company_name: "Rani Therapeutics Holdings, Inc."
filed_at: "2022-08-10T23:59:59+00:00"
generated_at: "2026-06-24T01:35:25.821669+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Rani Therapeutics Q2 net loss $16M; positive RT-102 Phase 1 results

## Summary
- Positive Phase 1 topline results for RT-102 (PTH capsule for osteoporosis): high bioavailability, well-tolerated, all endpoints met.
- Completed debt financing up to $45M with Avenue Capital Group; $15M funded at closing; cash runway extended into mid-2024.
- Cash and equivalents $97.2M at June 30, 2022 vs $117.5M at Dec 31, 2021.
- Net loss of $16.0M in Q2 2022 vs $5.5M in Q2 2021; R&D expenses rose to $9.5M.
- Near-term milestones: repeat-dose RT-102 results in Q4 2022, additional Phase 1 trial initiation in 2H 2022, pre-IND meeting with FDA.

## SEC filing metadata
- accession: 0000950170-22-016489
- form_type: 8-K
- ticker: RANI
- cik: 0001856725
- company_name: Rani Therapeutics Holdings, Inc.
- filed_at: 2022-08-10T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1856725/000095017022016489/0000950170-22-016489-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1856725/000095017022016489/rani-20220810.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-016489
- JSON: https://secwatch.observer/filing/0000950170-22-016489.json
- Plain text: https://secwatch.observer/filing/0000950170-22-016489.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.